ライフサイエンスコーパス: congenital heart block

1 s it pertains to ventricular arrhythmias and congenital heart block.

2 provide new insight into the pathogenesis of congenital heart block.

3 lained despite their strong association with congenital heart block.

4 bs, particularly 52Ro, in the development of congenital heart block.

5 tions of neonatal lupus (cardiac NL) include congenital heart block and cardiomyopathy.

6 (19%) in mothers with a previous child with congenital heart block and in 3 of 74 pregnancies (4%) i

7 Despite the near universal association of congenital heart block and maternal Abs to SSA/Ro and SS

8 ibodies give birth to children with complete congenital heart block and photosensitive skin lesions.

9 ne 400 mg daily to prevent the recurrence of congenital heart block associated with anti-SSA/Ro (anti

10 Rs), as did cardiac tissue from a fetus with congenital heart block (CHB) and an age-matched control.

11 ance in the description and understanding of congenital heart block (CHB) came in the 1970s with the

12 he recurrence rate of anti-SSA/Ro-associated congenital heart block (CHB) is 17%.

13 Congenital heart block (CHB) is a conduction abnormality

14 Congenital heart block (CHB) is a disease that affects t

15 Congenital heart block (CHB) is an autoimmune disease th

16 It is a widely held view that congenital heart block (CHB) is caused by the transplace

17 signature lesion of autoantibody-associated congenital heart block (CHB) is fibrosis of the conducti

18 Congenital heart block (CHB) is presumed to be caused by

19 Autoimmune associated congenital heart block (CHB) may result from pathogenic

20 Identification of isolated congenital heart block (CHB) predicts, with near certain

21 nd recurrence rates of autoimmune-associated congenital heart block (CHB) using information from the

22 IC) may be relevant in autoimmune-associated congenital heart block (CHB) where the obligate factor i

23 We report 16 infants with complete congenital heart block (CHB) who developed late-onset di

24 Congenital heart block (CHB), associated with antibodies

25 In congenital heart block (CHB), binding of maternal anti-S

26 -SSB/La are necessary for the development of congenital heart block (CHB), the low frequency suggests

27 r signaling in maternal anti-SSA/Ro-mediated congenital heart block (CHB).

28 tion of the atrioventricular node leading to congenital heart block (CHB).

29 IFN-stimulated genes in the pathogenesis of congenital heart block (CHB).

30 ated from 83 children (22 with rash, 35 with congenital heart block [CHB], 26 unaffected siblings) an

31 efficacious after in utero identification of congenital heart block, especially in fetuses with assoc

32 maternal autoantibodies with the genesis of congenital heart block, female BALB/c mice were immunize

33 syndrome, systemic lupus erythematosus, and congenital heart block from anti-Ro52 Ab-positive mother

34 There was a trend toward more congenital heart block in fetuses of women with previous

35 suggest that hydroxychloroquine may prevent congenital heart block in pregnancies exposed to SSA/Ro

36 Congenital heart block is considered a model of passivel

37 Anti-SSA/Ro-associated third-degree congenital heart block is irreversible, prompting a sear

38 4%) in mothers without a previous child with congenital heart block or rash (P=0.067).

39 The risk of having a subsequent child with congenital heart block ranges between 12-16%.

40 pathogenesis of neonatal lupus syndrome and congenital heart block reveals important information abo

41 he candidate antibodies to have a child with congenital heart block was at or below one in 50.

42 Congenital heart block was diagnosed in utero in 12 pati

43 (Preventive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH];